Aladin Farah, Lautscham Georg, Humphries Elizabeth, Coulson Judy, Blake Neil
Division of Medical Microbiology, University of Liverpool, Daulby Street, Liverpool, UK.
Cancer Immunol Immunother. 2007 Aug;56(8):1143-52. doi: 10.1007/s00262-006-0263-2. Epub 2006 Dec 2.
It is becoming increasingly apparent that the majority of tumours display defects in the MHC class I antigen processing pathway, particularly low levels of the transporters-associated with antigen processing (TAP) and tapasin. Thus, immunotherapy approaches targeting such tumours with CD8+ cytotoxic T lymphocytes (CTL) requires strategies to overcome these defects. Previously we had identified an antigen processing pathway by which cytosolically derived hydrophobic peptides could be presented in the absence of TAP. Here we show in the tapasin-negative cell line 721.220 that a number of these hydrophobic TAP-independent peptides can also be presented in a tapasin-independent manner. Yet when these experiments were extended to tumour cell lines derived from small cell lung cancer (SCLC), which we show to be tapasin deficient in addition to TAP-negative, the TAP-, tapasin-independent peptides were not presented. This lack of presentation could be rectified by pre-treatment of SCLC cells with IFNgamma. Alternatively, by directing the TAP-, tapasin-independent peptides into the endoplasmic reticulum (ER) via an ER signal sequence, these peptides were presented efficiently by SCLC cells. We infer from this data that the TAP-independent pathway for presentation of hydrophobic peptides generates a low concentration of peptide in the ER and, for tumour cells which also lack tapasin, this concentration of antigenic peptide is insufficient to load onto MHC class I molecules. Thus, for immunotherapeutic approaches to target SCLC and other tumours with defects in the MHC class I antigen processing pathway it will be important to consider strategies that address tapasin-defects.
越来越明显的是,大多数肿瘤在MHC I类抗原加工途径中存在缺陷,特别是与抗原加工相关的转运体(TAP)和TAP结合蛋白水平较低。因此,用CD8 +细胞毒性T淋巴细胞(CTL)靶向此类肿瘤的免疫治疗方法需要克服这些缺陷的策略。此前我们已经确定了一种抗原加工途径,通过该途径,胞质来源的疏水肽可以在没有TAP的情况下呈递。在这里,我们在TAP结合蛋白阴性细胞系721.220中表明,许多这些不依赖TAP的疏水肽也可以以不依赖TAP结合蛋白的方式呈递。然而,当这些实验扩展到源自小细胞肺癌(SCLC)的肿瘤细胞系时,我们发现除了TAP阴性外,这些细胞还缺乏TAP结合蛋白,不依赖TAP和TAP结合蛋白的肽并未呈递。通过用γ干扰素预处理SCLC细胞可以纠正这种缺乏呈递的情况。或者,通过内质网(ER)信号序列将不依赖TAP和TAP结合蛋白的肽引导到内质网中,这些肽可以被SCLC细胞有效呈递。我们从这些数据推断,疏水肽呈递的不依赖TAP途径在内质网中产生低浓度的肽,对于也缺乏TAP结合蛋白的肿瘤细胞,这种抗原肽浓度不足以加载到MHC I类分子上。因此,对于针对MHC I类抗原加工途径有缺陷的SCLC和其他肿瘤的免疫治疗方法,考虑解决TAP结合蛋白缺陷的策略将很重要。